In non-small-cell lung cancer (NSCLC) and various other cancers, mutations in nuclear factor erythroid 2-related factor 2 (NRF2) cause aberrant activation of NRF2 transcriptional activity, resulting in therapeutic resistance and poor survival.
Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.
